Seattle's Juno Therapeutics Pauses Trial After Patient Deaths

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

One of the most exciting new avenues in cancer research is the development of techniques to genetically re-engineer a patient’s own immune cells to destroy tumors. Several companies are racing to commercialize this technology. In the lead are Novartis NVS +1.09%, working with researchers at the University of Pennsylvania, and Juno Therapeutics, a roll-up of research at Memorial Sloan-Kettering Cancer Center In New York and the Fred Hutchinson Cancer Research Center in Seattle that raised $145 million from investors including Jeff Bezos earlier this year. The team of Celgene CELG -0.65% and Bluebird has also entered the field, as has Kite Pharmaceuticals.

Help employers find you! Check out all the jobs and post your resume.

Back to news